COX6B1 Antibody

What is COX6B1 and what applications are COX6B1 antibodies suitable for?

COX6B1 (Cytochrome c oxidase subunit 6B1) is a nuclear-encoded subunit that localizes to the intermembrane space of mitochondria, where it plays a critical role in cellular respiration. COX6B1 functions as the final electron donor in the electron transport chain, facilitating the creation of a proton gradient across the inner mitochondrial membrane essential for ATP production . This protein is crucial for the assembly of the cytochrome c oxidase (COX) dimer, which is composed of two monomers, each containing 13 subunits derived from both mitochondrial and nuclear origins .

COX6B1 antibodies can be applied in multiple experimental techniques:

The wide range of validated applications makes COX6B1 antibodies versatile tools for investigating mitochondrial function, respiratory chain complexes, and related diseases.

What are the optimal dilutions and experimental conditions for COX6B1 antibody applications?

Optimal working dilutions vary depending on the specific antibody, application, and sample type. Based on validated commercial antibodies, the following dilutions are generally recommended:

For optimal results in immunofluorescence studies, a protocol involving 4% formaldehyde fixation for 10 minutes followed by permeabilization in 0.1% PBS-Tween containing 1% BSA, 10% normal goat serum, and 0.3M glycine has been validated for COX6B1 detection .

What species reactivity do commercial COX6B1 antibodies demonstrate?

COX6B1 is highly conserved across species, allowing antibodies to recognize the protein in multiple organisms. Based on available products:

The high degree of conservation (93-100% sequence homology in mammals) makes most COX6B1 antibodies suitable for cross-species applications .

How can I validate COX6B1 antibody specificity in knockout or knockdown models?

Validating antibody specificity is crucial for reliable research results. For COX6B1, several approaches have been documented:

• CRISPR-Cas9 Knockout Validation:
  Recent studies have generated COX6B1 knockout (KO) HEK293 cell lines that can serve as negative controls. Complete absence of the 10-13 kDa band in Western blots from KO cells confirms antibody specificity .

• siRNA/shRNA Knockdown Controls:

  • Transfect cells with COX6B1-specific siRNA and control siRNA

  • Confirm knockdown efficiency by qRT-PCR (typically >80% reduction)

  • Perform Western blot with decreasing protein amounts (5, 10, 20 μg) to demonstrate proportional signal reduction in knockdown samples

• Overexpression Controls:
  The pcDNA3.1(+)-COX6B1 overexpression vector has been successfully used to validate antibody specificity and functional studies . The coding sequence can be amplified using the following primers:

  • Forward: 5′-ACCATGGCTGAAGACATCAAGACT-3′

  • Reverse: 5′-TCAGATCTTCCCAGGAAATG-3′

• Peptide Competition Assay:
  Pre-incubation of the antibody with the immunizing peptide should eliminate specific staining in validated applications.

For the most rigorous validation, combining multiple approaches is recommended, particularly when studying tissue samples where knockout models may not be available.

What are the experimental considerations when studying COX6B1 mutations in disease models?

COX6B1 mutations have been associated with mitochondrial diseases including encephalomyopathy, hydrocephalus, and cardiomyopathy . Key considerations include:

• Mutation-Specific Antibody Binding:

  • The common pathogenic mutations (R20C and R20H) are located in a region that affects protein folding and stability

  • These mutations disrupt a hydrogen bond network involving D18-R20-D36-R39, potentially affecting antibody recognition

  • For R20C mutation, predicted protein destabilization is higher (ΔΔG = 0.86 kcal/mol) compared to R20H (ΔΔG = 0.45 kcal/mol)

• Sample Preparation for Mutant Proteins:

  • Use gentle lysis conditions to preserve potentially unstable mutant proteins

  • Include protease inhibitors and maintain samples at 4°C throughout processing

  • Consider using protein stabilizing agents such as glycerol in buffers

• Control Selection:
  When studying disease-associated mutations, including the following controls is essential:

  • Wild-type COX6B1 expression constructs

  • Cell lines expressing pathogenic variants (R20C, R20H)

  • Alternative oxidase (AOX) expression to bypass electron transport chain defects

• Therapeutic Interventions Assessment:
  Several compounds have shown promise in rescuing COX6B1 mutation effects and can be included as experimental treatments:

  • 5-aminoimidazole-4-carboxamide ribonucleotide

  • Resveratrol

  • Ascorbate (vitamin C)

How does COX6B1 contribute to mitochondrial supercomplex formation, and how can this be studied?

COX6B1 plays a crucial role in respiratory chain supercomplex formation, with recent research highlighting its importance in early assembly steps:

• Supercomplex Analysis Methodologies:

  • Blue Native Polyacrylamide Gel Electrophoresis (BN-PAGE) is the gold standard for studying supercomplexes

  • Use 3-12% gradient gels for effective separation

  • Transfer high molecular weight proteins to PVDF membrane at 90V for 4 hours in modified transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol, 0.01–0.2% SDS)

• COX6B1's Role in Supercomplex Assembly:

  • COX6B1 knockouts show severely decreased proportion of high molecular weight supercomplexes (SCs) composed of Complexes I, III, and IV

  • In CR (calorie restriction) models, COX6B1 protein levels are increased in the SC fractions

  • Recent evidence indicates COX6B1 is essential for redox-sensitive early cytochrome c oxidase assembly steps, contrary to previous classifications as a late assembly factor

• Experimental Design for Supercomplex Studies:

  • Compare wild-type, COX6B1 knockout, and COX6B1-overexpressing samples

  • Use detergents like digitonin (0.5-1%) to solubilize intact supercomplexes

  • Apply complexome profiling techniques to identify assembly intermediates

  • Include mitochondrial markers for different compartments (matrix, inner membrane, intermembrane space)

• Key Findings in COX6B1 Knockout Models:

  • Complete loss of fully assembled Complex IV

  • Accumulation of early assembling subunits (COX4, MT-CO1, COX5A)

  • Evidence of partially assembled Complex IV modules incorporated directly into supercomplex structures, supporting the 'cooperative assembly' model

What are the optimal sample preparation methods for COX6B1 detection in different applications?

Successful detection of COX6B1 requires specific sample preparation approaches tailored to each application:

• For Western Blotting:

  • Mitochondrial enrichment significantly improves signal-to-noise ratio

  • Differential centrifugation protocol: homogenize tissue/cells in isolation buffer (250 mM sucrose, 10 mM Tris-HCl pH 7.4, 0.1 mM EGTA), centrifuge at 1,000×g for 10 min, collect supernatant and centrifuge at 10,000×g for 10 min

  • Resuspend mitochondrial pellet in RIPA buffer supplemented with protease inhibitors

  • For whole cell lysates, include 1% Triton X-100 or 0.5% NP-40 in lysis buffer to solubilize mitochondrial membranes

• For Immunohistochemistry:

  • Fresh frozen sections: fix in cold acetone for 10 minutes

  • FFPE tissues: optimize antigen retrieval using Tris-EDTA buffer pH 9.0 (primary recommendation) or citrate buffer pH 6.0 (alternative)

  • Heat-induced epitope retrieval: 95-98°C for 15-20 minutes followed by 20-minute cool-down

• For Immunofluorescence:

  • Cultured cells: 4% paraformaldehyde fixation for 15 minutes at room temperature

  • For mitochondrial co-localization studies, pre-stain live cells with 100 nM MitoTracker Red for 15 minutes before fixation

  • Block with protein-free blocking buffer before primary antibody incubation

  • For optimal signal, use Alexa Fluor 488-labeled secondary antibodies with nuclear counterstain using TO-PRO-3

• For Co-immunoprecipitation of Mitochondrial Complexes:

  • Solubilize mitochondrial membranes with mild detergents (0.5-1% digitonin)

  • Maintain sample at 4°C throughout processing

  • Pre-clear lysates with protein A/G beads to reduce background

  • Include negative controls (isotype-matched IgG) and positive controls (input sample)

What are the most common technical challenges when working with COX6B1 antibodies and how can they be addressed?

Researchers commonly encounter several challenges when working with COX6B1 antibodies:

• Low Signal Intensity:

  • Problem: COX6B1 is a low molecular weight protein (10 kDa) expressed at moderate levels

  • Solution: Use higher antibody concentration (1:500-1:1000), longer incubation times (overnight at 4°C), and more sensitive detection systems like ECL-Plus

• Multiple Bands in Western Blot:

  • Problem: Detection of non-specific bands or post-translational modifications

  • Solution: Include positive controls (recombinant COX6B1) and negative controls (COX6B1 knockout lysates); use gradient gels (4-20%) for better separation of low molecular weight proteins

• Background in Immunostaining:

  • Problem: Non-specific staining in mitochondria-rich tissues

  • Solution: More stringent blocking (3% BSA + 5% normal serum), longer washing steps (5×5 minutes), and reduced primary antibody concentration; include an absorption control with immunizing peptide

• Variable Results in Diseased Tissues:

  • Problem: Inconsistent staining patterns in pathological samples

  • Solution: Use freshly prepared samples when possible; for archived samples, validate fixation time effects; include normal adjacent tissue as internal control

• Supercomplex Preservation:

  • Problem: Dissociation of supercomplexes during sample preparation

  • Solution: Use digitonin instead of Triton X-100 for solubilization; keep samples cold at all times; avoid freeze-thaw cycles; add glycerol (10%) to stabilize protein complexes

How can I optimize detection of COX6B1 in co-localization studies with other mitochondrial proteins?

Co-localization studies require careful optimization to generate reliable data:

• Sequential Immunostaining Protocol:

  • Fix cells with 4% paraformaldehyde (15 min, room temperature)

  • Permeabilize with 0.1% Triton X-100 in PBS (10 min)

  • Block with 3% BSA, 10% normal serum in PBS (1 hour)

  • Incubate with COX6B1 primary antibody (1:100, overnight at 4°C)

  • Apply first secondary antibody (2 hours, room temperature)

  • Block again with 5% serum from species of second secondary antibody

  • Incubate with second primary antibody (different species than COX6B1 antibody)

  • Apply second secondary antibody with different fluorophore

• Validated Antibody Combinations:

  • For complex IV components: pair rabbit anti-COX6B1 with mouse anti-MTCO1

  • For mitochondrial markers: combine mouse anti-COX6B1 with rabbit anti-TOM20

  • For supercomplex studies: use rabbit anti-COX6B1 with mouse anti-Complex III Core 2

• Confocal Microscopy Acquisition Settings:

  • Use sequential scanning to avoid fluorophore crosstalk

  • Establish negative controls for each channel separately

  • Apply appropriate thresholds based on control samples

  • Collect Z-stacks (0.3-0.5 μm steps) for proper colocalization analysis

  • Use Pearson's correlation coefficient or Manders' overlap coefficient for quantification

• Super-Resolution Approaches:

  • For detailed suborganelle localization, STORM or STED microscopy provides superior resolution

  • Sample preparation requires specific fluorophores (Alexa 647 or ATTO dyes)

  • Mounting media optimization: use glucose oxidase/catalase oxygen scavenging system for STORM

• Live-Cell Imaging Considerations:

  • For dynamic studies, consider COX6B1-GFP fusion protein expression

  • Validate that fusion protein localizes correctly to mitochondria

  • Use Airyscan or spinning disk confocal microscopy for reduced phototoxicity

  • Maintain physiological conditions (37°C, 5% CO2) during imaging

How does COX6B1 overexpression protect against ischemia/reperfusion-induced neuronal damage?

Recent research has revealed a neuroprotective role for COX6B1 in ischemia/reperfusion (I/R) injury models:

• Molecular Mechanisms of Protection:

  • COX6B1 overexpression increases BCL-2 (anti-apoptotic) protein expression

  • Increases mitochondrial cytochrome c retention

  • Decreases BCL2-associated X (pro-apoptotic) protein levels

  • Reduces cytosolic cytochrome c release that would trigger apoptosis

  • Decreases cytosolic Ca2+ levels during I/R injury

• Experimental Models for Studying Protective Effects:

  • Oxygen-glucose deprivation/reoxygenation (OGD/R) in primary hippocampal neurons

  • Comparison groups should include:

    • Control group: untreated cells

    • Empty vector (EV) group: cells transfected with pcDNA3.1(+)-EV

    • COX6B1 group: cells transfected with pcDNA3.1(+)-COX6B1

    • EV + I/R group: OGD cells transfected with pcDNA3.1(+)-EV

    • I/R group: untransfected OGD cells

    • COX6B1 + I/R group: OGD cells transfected with pcDNA3.1(+)-COX6B1

• Quantification Parameters:

  • Cell viability (MTT or CCK-8 assay)

  • Apoptosis rates (Annexin V/PI staining)

  • Mitochondrial membrane potential (JC-1 staining)

  • Intracellular Ca2+ levels (Fluo-3/AM staining)

  • Western blot analysis of apoptosis-related proteins

These findings suggest potential therapeutic strategies for cerebrovascular diseases through COX6B1-targeted interventions.

What role does COX6B1 play in early vs. late cytochrome c oxidase assembly?

Recent research has significantly revised our understanding of COX6B1's role in complex IV assembly:

• Traditional vs. Current Understanding:

  • Traditional view: COX6B1 was considered a late-stage assembly factor incorporated into an almost complete complex IV

  • Current evidence: COX6B1 is indispensable for redox-sensitive early assembly steps of complex IV

• Key Experimental Evidence:

  • Complete loss of assembled complex IV in COX6B1 knockout cells

  • Preservation of early assembly subunits (COX4, MT-CO1, COX5A) in knockout models

  • Severe reduction of MT-CO2-containing intermediates in the absence of COX6B1

  • Incorporation of partially assembled complex IV modules directly into supercomplex structures in COX6B1 knockout backgrounds

• Assembly Pathway Analysis:

  • In wild-type cells: distribution of all 13 complex IV subunits in mature complex IV-containing species

  • In COX6B1 knockout: eight early-assembling subunits accumulate in assembly intermediates

  • Expression of alternative oxidase (AOX) in COX6B1 knockout cells enables further assembly progression, suggesting redox state importance

• Experimental Approaches to Study Assembly:

  • Complexome profiling through mass spectrometry analysis of blue native gel slices

  • Pulse-chase labeling of mitochondrial translation products

  • Assembly intermediate immunocapture followed by proteomic analysis

  • Comparison of different knockout models (COX6B1 vs. COX4 knockouts)

These findings support the 'cooperative assembly' model for respiratory chain biogenesis and highlight COX6B1's more fundamental role than previously recognized.

How do different pathogenic mutations in COX6B1 (R20C vs. R20H) affect protein function and antibody recognition?

COX6B1 pathogenic mutations, particularly R20C and R20H, have distinct effects on protein stability and function:

• Structural Impact Assessment:

  • Arginine R20 forms part of a hydrogen bond network (D18-R20-D36-R39) that orients the flexible N-terminal tail

  • R20C mutation (present study): more severe predicted destabilization (ΔΔG = 0.86 kcal/mol)

  • R20H mutation (previously reported): less severe predicted destabilization (ΔΔG = 0.45 kcal/mol)

• Differential Functional Consequences:

  • Both mutations lead to COX deficiency but with varying severity

  • R20C: associated with encephalomyopathy, hydrocephalus, and hypertrophic cardiomyopathy

  • Clinical severity correlates with the degree of predicted protein destabilization

• Antibody Recognition Considerations:

  • Antibodies targeting epitopes containing or near R20 may show diminished binding to mutant proteins

  • Terminal-directed antibodies (N or C-terminal) are less affected by these central domain mutations

  • Using multiple antibodies targeting different epitopes is recommended for studying pathogenic variants

• Rescue Experiments:

  • Wild-type COX6B1 cDNA complementation restores COX activity

  • 5-aminoimidazole-4-carboxamide ribonucleotide, resveratrol, and ascorbate supplementation improve mitochondrial function in patient fibroblasts

  • Therapeutic interventions should be evaluated in both mutation types to determine efficacy differences

For comprehensive research on COX6B1 pathogenic variants, combining structural analysis, functional assays, and therapeutic testing is essential.